Neuroblastoma treatment in the post-genomic era

Esposito, Maria Rosaria; Aveic, Sanja; Seydel, Anke; Tonini, Gian Paolo

doi:10.1186/s12929-017-0319-y

Cited by 99 publications

(86 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Certain patients with malignant tumors were treated with chemotherapy, which consisted of different combinations of vincristine, cisplatin, etoposide, cyclophosphamide, and carboplatin (13)(14)(15). Additionally, some patients gave up treatment after the diagnosis.…”

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Lin

Chen

et al. 2018

Iran J Pediatr

View full text Add to dashboard Cite

Background: The true incidence of peripheral neuroblastic tumors (PNTs) in children is unknown. This study aims to review and analyze clinical data on the diagnosis and management of pediatric PNTs. Methods: Between 2007 and 2016, a total of 43 pediatric patients admitted to our institute with PNTs were reviewed. Results: The series comprised of 23 males and 20 females with a median age of 1.2 years old. Among the 43 PNTs, 26 tumors originated from the abdomen, 13 from the thorax and four from other primary sites. A total of 16 tumors were identified in routine examinations. Abdominal pain and distension were the main clinical manifestations of abdominal PNTs, while coughing was the most frequent presenting symptom of thoracic PNTs. Elevated vanillylmandelic acid level in the urine over 24 hours was observed in 18 neuroblastoma cases and three ganglioneuroblastoma cases. Neuroblastoma was the most common type of PNT that was reported in 30 (69.8%) patients, followed by ganglioneuroblastoma, which was diagnosed in 11 (25.6%) patients. Only 2 (4.6%) patients were diagnosed with ganglioneuroma. A total of 12 cases were stage, six cases were stage II, three cases were stage III, 18 cases were stage IV, and four cases were stage IVs. The overall two year survival rate was 62.9%, which was related to pathological type, Shimada classification, stage, and primary site. Conclusions: Pediatric PNTs have different clinical characteristics and outcomes. Imaging and laboratory data may be useful for the differentiation of PNTs. This study will help pediatric surgeons be aware of the possible manifestations of PNTs in children.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Lin

Chen

et al. 2018

Iran J Pediatr

View full text Add to dashboard Cite

show abstract

“…The incorporation of three distinct phases of therapy has improved outcomes for high-risk NB: intensive induction therapy, myeloablative chemotherapy with autologous hematopoietic stem cell rescue, and treatment of minimal residual disease (MRD). In recent years, the survival rate of patients with NB has been increasing due to the intensi cation of treatment methods [16][17][18]. Even after these treatments, the relapse rate is still higher than 40%, which leads to the use of treatments such as isotretinoin and monoclonal anti-GD2 antibodies in MRD-positive patients after transplantation [19].…”

Section: Discussionmentioning

confidence: 99%

Results of the Neuroblastoma-2015 protocol for treating neuroblastoma in China: experience from multiple centers

Yan

Jin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The collaborative efforts of the Chinese Childhood Cancer Organization (CCCG) have led to an improved understanding of NB biology, standardized classification, and stratification strategies, thereby improving outcomes in China. We aimed to assess the NB-2015 protocol developed by the CCCG in 2015 and to evaluate the degree of impact of autologous peripheral blood stem cell transplantation (APBSCT). Methods: This study enrolled NB patients from seven medical centers in China between 2015 and 2018. In this paper, we retrospectively analyzed the clinical characteristics of 161 patients and used their effect on survival as an outcome measure. Results: The 3-year event-free survival (EFS) rates were 95.5%, 91.6%, and 51.1% in the low-, medium-, and high-risk groups, respectively. In total, 3 out of 7 (42.8%) patients with stage 2B disease, none of whom had MYCN amplifications, relapsed. A total of 47 of the 78 patients in the high-risk group underwent external-beam radiation to the primary tumor bed (dose ranging from 18 to 36 Gy). There was a significant difference in efficacy between patients who received radiation therapy and those who did not (3-year OS P = 0.041). Within the high-risk group, The 3-year EFS rates of the patients with and without APBSCT were 72.6% and 37.1%, respectively (P=0.008).Conclusions: This study showed that satisfactory results were obtained without fatal complications using the NB-2015 protocol. Chemotherapy should be intensified in the stage 2B group. APBSCT can effectively improve the survival rate of NB patients, especially high-risk patients.

show abstract

“…Neuroblastoma is the most common embryonal malignancy of the sympathetic nervous system of early childhood [64]. Here, a single point mutation of Nme-1 that results in a Ser120-Gly substitution has been reported for 21% of patients with advanced neuroblastoma, with gain of chromosomal segment 17q21 also seen.…”

Section: Therapeutic Potential Of Cppmentioning

confidence: 99%

A competitive cell-permeable peptide impairs Nme-1 (NDPK-A) and Prune-1 interaction: therapeutic applications in cancer

Ferrucci

Pennino

Siciliano

et al. 2018

Laboratory Investigation

View full text Add to dashboard Cite

The understanding of protein-protein interactions is crucial in order to generate a second level of functional genomic analysis in human disease. Within a cellular microenvironment, protein-protein interactions generate new functions that can be defined by single or multiple modes of protein interactions. We outline here the clinical importance of targeting of the Nme-1 (NDPK-A)-Prune-1 protein complex in cancer, where an imbalance in the formation of this protein-protein complex can result in inhibition of tumor progression. We discuss here recent functional data using a small synthetic competitive cell-permeable peptide (CPP) that has shown therapeutic efficacy for impairing formation of the Nme-1-Prune-1 protein complex in mouse preclinical xenograft tumor models (e.g., breast, prostate, colon, and neuroblastoma). We thus believe that further discoveries in the near future related to the identification of new protein-protein interactions will have great impact on the development of new therapeutic strategies against various cancers.

show abstract

Neuroblastoma treatment in the post-genomic era

Cited by 99 publications

References 149 publications

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Results of the Neuroblastoma-2015 protocol for treating neuroblastoma in China: experience from multiple centers

A competitive cell-permeable peptide impairs Nme-1 (NDPK-A) and Prune-1 interaction: therapeutic applications in cancer

Contact Info

Product

Resources

About